Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BCRX 
BioCryst Pharmaceuticals Inc (BCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: BCRX (1-star) is a SELL. SELL since 2 days. Profits (12.66%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $16.58
Year Target Price $16.58
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.12% | Avg. Invested days 23 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.96B USD | Price to earnings Ratio - | 1Y Target Price 17.44 |
Price to earnings Ratio - | 1Y Target Price 17.44 | ||
Volume (30-day avg) - | Beta 1.1 | 52 Weeks Range 6.01 - 11.31 | Updated Date 06/29/2025 |
52 Weeks Range 6.01 - 11.31 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.62% | Operating Margin (TTM) 14.59% |
Management Effectiveness
Return on Assets (TTM) 4.54% | Return on Equity (TTM) -1925.37% |
Valuation
Trailing PE - | Forward PE 53.48 | Enterprise Value 2456529537 | Price to Sales(TTM) 3.89 |
Enterprise Value 2456529537 | Price to Sales(TTM) 3.89 | ||
Enterprise Value to Revenue 4.88 | Enterprise Value to EBITDA 51.62 | Shares Outstanding 209250000 | Shares Floating 207019666 |
Shares Outstanding 209250000 | Shares Floating 207019666 | ||
Percent Insiders 1.2 | Percent Institutions 85.56 |
Analyst Ratings
Rating 4.42 | Target Price 16.58 | Buy 5 | Strong Buy 6 |
Buy 5 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioCryst Pharmaceuticals Inc
Company Overview
History and Background
BioCryst Pharmaceuticals Inc. was founded in 1986. It has focused on discovering, developing, and commercializing novel small-molecule medicines that address unmet medical needs. Initially focused on structure-guided drug design, BioCryst has evolved into a commercial-stage biopharmaceutical company.
Core Business Areas
- Hereditary Angioedema (HAE): BioCryst's primary focus is on HAE, with ORLADEYOu00ae (berotralstat) as its main product. This segment encompasses the development, manufacturing, and commercialization of treatments for HAE and related conditions.
- Rare Diseases: BioCryst is expanding its portfolio to include treatments for other rare diseases, leveraging its expertise in small-molecule drug development. It has programs targeting complement-mediated diseases.
Leadership and Structure
The company is led by Jon Stonehouse (CEO). Its organizational structure includes research and development, commercial operations, finance, and administrative functions. The board of directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- ORLADEYOu00ae (berotralstat): ORLADEYO is an oral, once-daily therapy for the prevention of HAE attacks in adult and pediatric patients 12 years and older. It has captured a significant share of the HAE prophylaxis market. Competitors include Takeda's TAKHZYRO (lanadelumab) and CSL Behring's HAEGARDA (C1 esterase inhibitor).
- RAPIVABu00ae (peramivir): RAPIVAB is an intravenous neuraminidase inhibitor used to treat acute uncomplicated influenza. Its usage is seasonal. Competitors include Tamiflu (oseltamivir) and Xofluza (baloxavir marboxil).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The rare disease segment is growing, driven by unmet medical needs and orphan drug designations.
Positioning
BioCryst is a commercial-stage biopharmaceutical company with a strong position in the HAE market due to ORLADEYO. The company focuses on developing oral therapies for rare diseases, providing a competitive advantage.
Total Addressable Market (TAM)
The HAE market is estimated to be worth several billion USD annually. BioCryst, with ORLADEYO, aims to capture a significant portion of this TAM. The total addressable market for complement mediated diseases is potentially even larger.
Upturn SWOT Analysis
Strengths
- Strong position in the HAE market with ORLADEYO
- Oral therapy providing convenience for patients
- Experienced management team
- Focus on rare diseases with unmet medical needs
- Strong intellectual property portfolio
Weaknesses
- Reliance on a limited number of products
- Competition from established therapies
- Potential for generic erosion
- Dependence on successful clinical trials for pipeline products
- Smaller market capitalization compared to competitors
Opportunities
- Expansion into new indications and rare diseases
- Geographic expansion
- Strategic partnerships and collaborations
- Development of next-generation therapies
- Increasing awareness and diagnosis of HAE
Threats
- Competition from existing and emerging therapies
- Regulatory hurdles and delays
- Pricing pressures and reimbursement challenges
- Clinical trial failures
- Adverse events or safety concerns
Competitors and Market Share
Key Competitors
- TAK
- CSL
Competitive Landscape
BioCryst has an advantage with its oral therapy, ORLADEYO, which offers convenience compared to injectable competitors. However, competitors like Takeda and CSL Behring have established market presence and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: BioCryst has experienced significant revenue growth driven by the launch and adoption of ORLADEYO.
Future Projections: Analyst estimates project continued revenue growth for ORLADEYO and potential contributions from pipeline products. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding the commercial reach of ORLADEYO, advancing pipeline programs in complement-mediated diseases, and exploring strategic partnerships.
Summary
BioCryst is a growing biopharmaceutical company with a strong position in the HAE market thanks to ORLADEYO. The company is seeing increasing revenue and approaching profitability. BioCryst needs to continue to innovate and develop its pipeline, while also managing competition from established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Presentations
- Analyst Reports
- Industry Research Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioCryst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 1994-03-03 | CEO, President & Executive Director and Interim CFO, Principal Accounting Officer Mr. Jon P. Stonehouse | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 580 | Website https://www.biocryst.com |
Full time employees 580 | Website https://www.biocryst.com | ||
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.